Jorge Silva - MoonLake Immunotherapeuti CEO CoFounder
| MLTX Stock | USD 54.43 0.19 0.35% |
Insider
Jorge Silva is CEO CoFounder of MoonLake Immunotherapeutics
| Age | 46 |
| Address | Dorfstrasse 29, Zug, Switzerland, 6300 |
| Phone | 41 415108022 |
| Web | https://www.moonlaketx.com |
MoonLake Immunotherapeuti Management Efficiency
The company has return on total asset (ROA) of (0.1332) % which means that it has lost $0.1332 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.168) %, meaning that it created substantial loss on money invested by shareholders. MoonLake Immunotherapeuti's management efficiency ratios could be used to measure how well MoonLake Immunotherapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to rise to -0.1 in 2024. At this time, MoonLake Immunotherapeuti's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 11.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| George Eldridge | Aerovate Therapeutics | 61 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Mike Ouimette | Pliant Therapeutics | 51 | |
| Narinderjeet MS | Arcellx | 52 | |
| Peter Moesta | Compass Therapeutics | N/A | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Christopher MD | Arcellx | 44 | |
| Quoc LeNguyen | 89bio Inc | 56 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| John Nuss | Ventyx Biosciences | 65 | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Johannes Hull | Pliant Therapeutics | 49 | |
| CFA CFA | Travere Therapeutics | 40 | |
| MD MBA | Pliant Therapeutics | 47 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Dean MD | Pliant Therapeutics | N/A | |
| Christopher MD | Nuvalent | 55 | |
Management Performance
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 |
MoonLake Immunotherapeuti Leadership Team
Elected by the shareholders, the MoonLake Immunotherapeuti's board of directors comprises two types of representatives: MoonLake Immunotherapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MoonLake. The board's role is to monitor MoonLake Immunotherapeuti's management team and ensure that shareholders' interests are well served. MoonLake Immunotherapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MoonLake Immunotherapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tino Anthamatten, Market Marketing | ||
| Luciana Marques, People HR | ||
| Jorge Silva, CEO CoFounder | ||
| Nicolas Mosimann, General Counsel | ||
| Annett Zippel, Director Culture | ||
| Joana Cortez, Director Compliance | ||
| Oliver Daltrop, Chief Officer | ||
| Nuala Brennan, Chief Officer | ||
| Kristian Reich, CoFounder Officer | ||
| Matthias Bodenstedt, Chief Officer | ||
| Carla Bretes, Director Development |
MoonLake Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MoonLake Immunotherapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 2.93 B | ||||
| Shares Outstanding | 63.06 M | ||||
| Shares Owned By Insiders | 15.22 % | ||||
| Shares Owned By Institutions | 98.14 % | ||||
| Number Of Shares Shorted | 8 M | ||||
| Price To Book | 7.01 X | ||||
| EBITDA | (54.11 M) | ||||
| Net Income | (44.08 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.